Objective:

To evaluate the effectiveness of complement inhibitor therapy in managing geographic atrophy (GA) in a patient with significant vision impairment, particularly in the context of shifting treatment paradigms.

Key Findings:

• Complement inhibitor therapy has shifted GA management from watchful waiting to proactive treatment, addressing both clinical and functional symptoms.
• The therapy does not restore lost vision but slows the progression of atrophy by approximately 20% to 30% over 2 to 3 years, which is crucial for maintaining quality of life.
• The patient demonstrated a clear need for intervention due to functional symptoms and imaging evidence of lesion growth.

Interpretation:

The case illustrates the potential of complement inhibitors to preserve vision and improve quality of life in patients with GA, despite the absence of vision restoration, highlighting the need for further research.

Limitations:

• Current imaging tools cannot quantify individual rates of GA progression, and the therapy's long-term effects beyond trial data remain uncertain, including potential side effects.

Conclusion:

Complement inhibitor therapy represents a significant advancement in the management of geographic atrophy, offering hope for preserving vision and independence in affected patients, while emphasizing the importance of ongoing monitoring.